Cevimeline Hydrochloride
8 NDCs across 6 manufacturers|7 Generic,1 Brand
Cevimeline Hydrochloride is used to treat xerostomia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jan 11, 2000, and the first generic was approved Aug 25, 2011. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient.
Cevimeline Hydrochloride is available as 8 NDCs from 6 manufacturers (7 generic, 1 brand), with NADAC prices from $0.73 to $8.59 per EA — the most expensive product costs about 12× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
8
7G / 1B
Manufacturers
6
competing in market
Price Spread
$0.73 – $8.59
per EA
7d Activity
avg +3.0% WoW · of 8 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Cosette Pharmaceuticals, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Cholinergic Receptor Agonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing CEVIMELINE HYDROCHLORIDE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
EVOXAC 30 MG CAPSULE | $8.5909 per EA | — |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
CEVIMELINE HCL 30 MG CAPSULE | $0.7289 per EA | +2.95% |
Frequently Asked Questions
What is Cevimeline Hydrochloride used to treat?
Cevimeline Hydrochloride is used to treat xerostomia, per the National Library of Medicine's MED-RT classification.
When did Cevimeline Hydrochloride become available as a generic?
FDA approved the first generic Cevimeline Hydrochloride (ANDA) on Aug 25, 2011. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How many Cevimeline Hydrochloride products are on the market?
The Cevimeline Hydrochloride drug market contains 8 NDCs from 6 manufacturers — 7 generic and 1 brand product.
What is the price range for Cevimeline Hydrochloride?
NADAC reference prices for Cevimeline Hydrochloride range from $0.7289 to $8.5909 per EA — the most expensive product costs about 12× the cheapest.
Is generic Cevimeline Hydrochloride cheaper than brand?
The average generic NADAC for Cevimeline Hydrochloride is $0.7289 per EA, versus $8.5909 for brand-labeled products — brand versions average about 12× the generic price.
Which manufacturers make Cevimeline Hydrochloride?
6 manufacturers list Cevimeline Hydrochloride in NADAC. Ranked by number of NDCs, the largest are Cosette Pharmaceuticals, Inc. (2), Advagen Pharma Ltd. (2), Rising Pharma Holdings Inc. (1), Aurobindo Pharma Limited (1), Hikma Pharmaceuticals USA Inc. (1).
How has the price of Cevimeline Hydrochloride changed recently?
Over the past 7 days, 7 Cevimeline Hydrochloride NDCs rose and 0 fell, with a market-wide average change of +3.0%.